Thermo Fisher Scientific Inc. (NYSE:TMO) Position Trimmed by Buffington Mohr McNeal

Buffington Mohr McNeal cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 26,731 shares of the medical research company’s stock after selling 491 shares during the period. Thermo Fisher Scientific makes up about 2.3% of Buffington Mohr McNeal’s portfolio, making the stock its 15th largest holding. Buffington Mohr McNeal’s holdings in Thermo Fisher Scientific were worth $13,906,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $26,000. Peterson Financial Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at $27,000. Missouri Trust & Investment Co acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Endeavor Private Wealth Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Finally, RPg Family Wealth Advisory LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 34,850 shares of company stock worth $19,123,197 over the last ninety days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $583.43 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The business’s 50-day moving average price is $533.60 and its two-hundred day moving average price is $569.81. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market capitalization of $223.16 billion, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. Evercore ISI lowered their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, TD Cowen upped their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.